Exhibit 99.01

            Cellegy Pharmaceuticals Announces Retirement of Director,
                             Dr. Ronald J. Saldarini

South San Francisco,  California,  December 11, 2003 - Cellegy  Pharmaceuticals,
Inc. (Nasdaq NM: CLGY) announced today that one of its directors,  Dr. Ronald J.
Saldarini has resigned from its board.

Cellegy's  Chief Executive  Officer K. Michael Forrest said, "Dr.  Saldarini has
been on our Board since 1999 and has made many  significant  contributions  over
the years. His retirement is well-earned. While we regret that he will no longer
be active with the Company,  we would like to thank him for his  dedication  and
service to Cellegy and its  shareholders.  We will miss him as a colleague and a
friend."

Cellegy Pharmaceuticals is a specialty biopharmaceuticals company engaged in the
development   and  marketing  of   prescription   drugs  for  the  treatment  of
gastroenterology disorders, sexual dysfunction,  and nitric oxide donors for the
treatment of certain cancers.

For More Information:

Richard Juelis                          K. Michael Forrest
Vice President, Finance & CFO           President & CEO
www.cellegy.com